Article Sidebar
Published:
Jul 3, 2017DOI:
10.4314/tjpr.v16i6.1Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Nanoemulsion formulation of Abatacept for lupus nephritis therapy
Abstract
Purpose: To formulate a nanoemulsion preparation of abatacept and evaluate its treatment efficacy in a C57BL/6 J mouse model of lupus nephritis (LN).
Methods: An abatacept nanoemulsion formulation was prepared using coarse homogenization followed by high-energy ultrasonication. The formulation was assessed for particle size and charge, morphology, and stability. C57BL/6 J mice treated with pristane (to create a mouse model of LN) received subcutaneous injections of the abatacept formulation, and the in vivo efficacy and immunological profiles were evaluated.
Results: The mean diameter of the nanoglobules ranged from 110 to 148 nm with a polydispersity index of < 1, and the formulation was stable for 3 months at 22 – 28 °C. The LN-model mice that were treated with the nanoemulsion formulation of abatacept showed a marked reduction in immune complexes, improved renal function and decreased expression of IL-4 and IFN-γ compared with untreated LN-model mice.
Conclusion: The nanoemulsion formulation of abatacept is a promising agent in the treatment of refractory LN. A systematic clinical trial is necessary to establish its long-term efficacy.
Keywords: Nanoemulsion, Abatacept, Lupus nephritis, Beta-1 integrin, Immunological profile
